Brief: Genethon, Hansa Biopharma Start Phase 2 Trial Of Imlifidase
03/12/2024 11:03
Dec 3 (Reuters) - Hansa Biopharma AB HNSA.ST :
* GENETHON AND HANSA BIOPHARMA ANNOUNCE INITIATION OF A
PHASE 2
TRIAL OF IMLIFIDASE AS A PRE-TREATMENT TO GNT-0003 IN SEVERE
CRIGLER-NAJJAR SYNDROME
Source text: ID:nBw9zbmFGa
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS